BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen Y, Xia M, Zhang J, Xu L, Yang J, Chen A, Miao F, Ferrone S, Xie W. IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells. Mol Immunol 2009;46:2045-53. [PMID: 19428110 DOI: 10.1016/j.molimm.2009.03.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Docta RY, Ferronha T, Sanderson JP, Weissensteiner T, Pope GR, Bennett AD, Pumphrey NJ, Ferjentsik Z, Quinn LL, Wiedermann GE, Anderson VE, Saini M, Maroto M, Norry E, Gerry AB. Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer. Hepatology. 2019;69:2061-2075. [PMID: 30561769 DOI: 10.1002/hep.30477] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
2 Jin YJ, Byun S, Han S, Chamberlin J, Kim D, Kim MJ, Lee Y. Differential alternative splicing regulation among hepatocellular carcinoma with different risk factors. BMC Med Genomics 2019;12:175. [PMID: 31856847 DOI: 10.1186/s12920-019-0635-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Luo X, Cui H, Cai L, Zhu W, Yang WC, Patrick M, Zhu S, Huang J, Yao X, Yao Y, He Y, Ji Y. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit. Front Immunol 2020;11:623. [PMID: 32425926 DOI: 10.3389/fimmu.2020.00623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Liu Q, Tian Y, Li Y, Zhang W, Cai W, Liu Y, Ren Y, Liang Z, Zhou P, Zhang Y, Bao Y, Li Y. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma. J Immunother Cancer 2020;8:e001748. [PMID: 33323464 DOI: 10.1136/jitc-2020-001748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Li Z, Gong H, Liu Q, Wu W, Cheng J, Mei Y, Chen Y, Zheng H, Yu X, Zhong S, Li Y. Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy. Immunology 2020;159:384-92. [PMID: 31849039 DOI: 10.1111/imm.13168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Pan N, Lu S, Wang W, Miao F, Sun H, Wu S, Nan D, Qiu J, Xu J, Zhang J. Quantification of classical HLA class I mRNA by allele-specific, real-time polymerase chain reaction for most Han individuals. HLA 2018;91:112-23. [PMID: 29178661 DOI: 10.1111/tan.13186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
7 Polak ME, Singh H. Tolerogenic and immunogenic states of Langerhans cells are orchestrated by epidermal signals acting on a core maturation gene module. Bioessays 2021;43:e2000182. [PMID: 33645739 DOI: 10.1002/bies.202000182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Pan N, Chen K, Qiu J, Sun H, Xu J, Miao F, Shi Q, Jiang W, Jin H, He Y, Xie W, Zhang J. Human leukocyte antigen class I alleles and haplotypes associated with primary hepatocellular carcinoma in persistent HBV-infected patients. Hum Immunol 2013;74:758-63. [PMID: 23459080 DOI: 10.1016/j.humimm.2013.02.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
9 Carretero FJ, Del Campo AB, Flores-Martín JF, Mendez R, García-Lopez C, Cozar JM, Adams V, Ward S, Cabrera T, Ruiz-Cabello F, Garrido F, Aptsiauri N. Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance. Cancer Immunol Immunother 2016;65:47-59. [PMID: 26611618 DOI: 10.1007/s00262-015-1774-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
10 Xu L, Shen Y, Xia M, Miao F, Shen C, Xie W, Zhang J. Up-regulate HLA class I expression following hepatitis B virus transfection in a hepatocellular carcinoma cell line BEL7405. Immunol Invest 2010;39:621-34. [PMID: 20653429 DOI: 10.3109/08820131003792826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
11 Chai X, Han Y, Yang J, Zhao X, Liu Y, Hou X, Tang Y, Zhao S, Li X. Identification of the transcriptional regulators by expression profiling infected with hepatitis B virus. Clin Res Hepatol Gastroenterol 2016;40:57-72. [PMID: 26119596 DOI: 10.1016/j.clinre.2015.04.005] [Reference Citation Analysis]
12 Gu S, Lv L, Lin X, Li X, Dai J, Zhang J, Kong R, Xie W, Li J. Using structural analysis to explore the role of hepatitis B virus mutations in immune escape from liver cancer in Chinese, European and American populations. J Biomol Struct Dyn 2020;:1-11. [PMID: 33030111 DOI: 10.1080/07391102.2020.1830852] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Eckhardt I, Weigert A, Fulda S. Identification of IRF1 as critical dual regulator of Smac mimetic-induced apoptosis and inflammatory cytokine response. Cell Death Dis 2014;5:e1562. [PMID: 25501823 DOI: 10.1038/cddis.2014.498] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]